This week, our conversations are with Uwe Diegel, CEO of Lifeina, about their cooling technologies, and with Dirk Beher, CEO of FundaMental Pharma, about treatment resistant depression.

Times:

02:37 FundaMental Pharma

23:56 Lifeina

FundaMental

FundaMental Pharma is a preclinical biopharmaceutical company focused on developing new treatments for treatment‑resistant depression (TRD).

The company’s platform centres on proprietary dual‑acting modulators of the N‑methyl‑D‑aspartate receptor (NMDAR). These molecules simultaneously disrupt the pathological complex formed between NMDAR and the TRPM4 ion channel, while also acting as potent NMDAR antagonists. This dual mechanism is designed to intervene upstream in the  ...